Landscapes / Companies
GB002, Inc. not checked
FollowEvery new trial, moved date and filing, and a Monday email
Drugs
1
in active trials
Trials
0 active
2 since 2021
Drugs1
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
Tyrosine kinase inhibitor |
GB002, Inc., a wholly owned subsidiary of Gossamer Bio |
Phase 3 | Dec 2026Phase 3 trial completes | ||
| How it works | Blocks a kinase | ||||
| Next date | Dec 2026 · Phase 3 trial completes | ||||
| Also tested for | Pulmonary Arterial Hypertension | ||||
| Open drug page | |||||
About
- SEC filings
- None: it does not file with the US SEC
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 Industry-sponsored drug trials since 2021